Trump Imposes Up to 200 Percent Tariffs on Indian Generic Drugs, Raising Export Concerns

Trump announces a tiered tariff on generic medicines from India, starting at 0% for low‑cost items, rising to 100% on mid‑range drugs and up to 200% on high‑value products, aiming to protect U.S. manufacturers.

Indian Pharma Industry says the steep tariffs could raise prices for U.S. patients, squeeze profit margins, and push companies to shift focus toward specialty drugs, where pricing is less regulated.

U.S. Trade Officials estimate the measures will have limited effect on overall Indian export volumes, noting that many Indian firms already diversify markets and that the tariff applies only to a subset of generics.

Export Forecasts project India's pharmaceutical sales to exceed £280 billion by 2047, but analysts warn the new tariff could slow substantial growth in the generic segment and accelerate investment in higher‑margin specialty products.